Evidence map›Paper›PMID 31505087›Full record

ArticleCancer science2019

Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer.

Yoshinori Makino, Reiko Makihara-Ando, Takanori Ogawa, Hitoshi Sato, Yasushi Goto, Shintaro Kanda, Hidehito Horinouchi, Yutaka Fujiwara, Yuichiro Ohe, Noboru Yamamoto

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Yoshinori MakinoDepartment of Pharmacy, National Cancer Center Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0003-2739-6458
Reiko Makihara-AndoDepartment of Pharmacy, National Cancer Center Hospital, Tokyo, Japan.
Takanori OgawaDivision of Pharmacokinetics/Pharmacodynamics, Department of Pharmacology, Toxicology, and Therapeutics, School of Pharmacy, Showa University, Tokyo, Japan.
Hitoshi SatoDivision of Pharmacokinetics/Pharmacodynamics, Department of Pharmacology, Toxicology, and Therapeutics, School of Pharmacy, Showa University, Tokyo, Japan.
Yasushi GotoDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Shintaro KandaDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Hidehito HorinouchiDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0001-9090-801X
Yutaka FujiwaraDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0001-6981-0800
Yuichiro OheDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0002-6137-073X
Noboru YamamotoDepartment of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Showa University · JPJapan Clinical Cancer Research Organization · JPTokyo National Hospital · JP

Funding

National Cancer Center Research and Development Fund 23-A-16
6 · The paper itself

Abstract

This study determined individual optimal amrubicin doses for Japanese patients with lung cancer after platinum-based treatment. We carried out population pharmacokinetic and pharmacodynamic modeling incorporating gene polymorphisms of metabolizing enzymes and transporters. Fifty patients with lung cancer, who were given 35-40 mg/m

Indexed as

AdultAgedAged, 80 and overAnthracyclinesAntineoplastic AgentsArea Under CurveAsian PeopleBody Surface AreaCarcinoma, Non-Small-Cell LungDrug Administration ScheduleFemaleHumansJapanLung NeoplasmsMaleMembrane Transport ProteinsamrubicinamrubicinolAnthracyclinesAntineoplastic Agentscif nucleoside transporterMembrane Transport Proteinsamrubicinamrubicinollung cancerpharmacodynamicspharmacokinetics

Identifiers

PMID31505087
PMCPMC6825008
OpenAlexW2972363927

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.